课题基金 / 基金详情

Interference with Androgen Receptor and Its Ligands

Interference with Androgen Receptor and Its Ligands
干扰雄激素受体及其配体
批准号:
7963169
负责人:
JAMES L MOHLER
金额:
$63.3万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-07-01 至 2015-06-30

项目摘要

项目成果

JAMES L MOHLER的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结(见说明): 项目1促成了两项改变范式的发现。第一,雄激素受体(AR)途径 似乎对去势-复发性前列腺癌(CAP)的生长至关重要,尽管去势水平 循环中的睾丸雄激素。其次,去势--复发帽会产生较高的组织水平 睾酮(T)和双氢睾酮(DHT),AR的首选配体。内分泌产生的睾丸 雄激素为新疗法提供了一个靶点。应用新的治疗方法可能会带来进一步的进展 当帽细胞死亡达到最大值时,帽与雄激素剥夺疗法(ADT)同时进行 存活的细胞承受着最大的压力。拟议研究的中心假设是,上限可以是 通过对雄激素代谢和AR的协同攻击而治愈或缓解 与消除循环中的睾丸雄激素(内科或外科去势)不谋而合。为了 测试这一假设,并允许在高级CAP中进行适当的临床试验,反应 对ADT的评估将在去势后立即使用临床前模型进行。一般而言,单元格或 组织样本将在去势前和去势后12小时、1、2、4、8、16和草皮上进行。 去势对雄激素轴的影响将在体外4个水平和体内6个水平进行评估。这个 4)体外和体内水平的评估将包括1)雄激素代谢酶在 用qRT-PCR法测定mRNA水平,用免疫组织化学(IHC)法测定蛋白质水平;2)用 LC-MS;3)使用IHC调节PSA、NkxS.1和HK2的雄激素基因表达;以及4)细胞生长。 体内测量将包括进展时间和存活率。ADT后雄激素代谢将 使用雄激素敏感的CWR22细胞悬液进行研究,雄激素依赖的CWR22异种移植瘤和 新鲜的外科组织异种移植模型。ADT后雄激素代谢的变化对生存至关重要 在体外使用shRNA或药物以及在体内使用慢病毒shRNA和/或药物作为靶点(目标1)。睾丸 由肾上腺雄激素的内分泌代谢形成的雄激素将使用53-还原酶或 Sult2A1使用慢病毒感染分娩(目标2)。最后,将使用慢病毒AR shRNA去除AR 构建或AR降解小分子(目标3)。
英文摘要
PROJECT SUMMARY (See instructions): Project 1 has contributed to two paradigm changing discoveries. First, the androgen receptor (AR) pathway appears critical to the growth of castration-recurrent prostate cancer (CaP) in spite of castrate levels of circulating testicular androgens. Second, castration-recurrent CaP produces high tissue levels of testosterone (T) and dihydrotestosterone (DHT), the preferred AR ligand. Intracrine-produced testicular androgens present a target for novel therapies. Further advances may result from applying novel treatments to CaP coincidental with androgen deprivation therapy (ADT) when CaP cell death is at a maximum and surviving cells are under greatest stress. The central hypothesis ofthe proposed studies is that CaP can be cured or remission extended by a coordinated attack upon intracrine androgen metabolism and AR coincidental with elimination of circulating testicular androgens (medical or surgical castration). In order to test this hypothesis and allow the formulation of an appropriate clinical trial in advanced CaP, the response to ADT will be assessed using preclinical models in the immediate post-castration period. In general, cell or tissue sampling will be conducted just prior to castration and 12h and 1, 2, 4, 8, 16 and SOd after "castration." The effect of castration upon the androgen axis will be assessed on 4 levels in vitro and 6 levels in vivo. The 4 levels of assessment in vitro and in vivo will include 1) changes in androgen metabolism enzymes at the mRNA level using qRT-PCR and protein level using immunohistochemistry (IHC); 2) androgen levels using LC-MS; 3) androgen-regulated gene expression using IHC for PSA, NkxS.1 and hK2; and 4) cell growth. Measures in vivo will include 5) time to progression and 6) survival. Androgen metabolism after ADT will be studied using androgen-sensitive CWR22 cell suspensions, the androgen-dependent CWR22 xenograft and a fresh surgical tissue xenograft model. Changes in androgen metabolism critical for survival after ADT will be targeted using shRNA or drug in vitro and lentiviral shRNA and/or drug in vivo (Aim 1). Testicular androgens formed by intracrine metabolism of adrenal androgens will be removed using 53-reductase or Sult2A1 delivered using lentiviral infection (Aim 2). Finally, AR will be removed using lentiviral AR shRNA constructs or AR degrading small molecules (Aim 3).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Interference with Androgen Receptor and Its Ligands
ImmunoAnalysis and Research Specimen Management
ImmunoAnalysis and Research Specimen Management
CORE B
海外基金